Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion
Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance may attract new institutional buying and support the stock's valuation.
Market read
The report provides fresh earnings data and guidance that can move Illumina and related biotech stocks.
What to watch
Higher freight and memory costs could pressure margins if they persist, and research consumables remain weak.
Background
Illumina is a leading provider of DNA sequencing systems and consumables, a key player in genomics.
Ticker impact
Illumina reported Q2 2026 results with revenue up 9.5% to $1.16B and raised full-year guidance.
Potential short‑term price rally of 3‑5% as investors price in higher revenue and EPS outlook.
The company delivered better-than-expected revenue and EPS, and increased guidance, which historically moves the stock positively.
Market effects
Positive for genomics and life‑science equipment sector as Illumina's growth signals demand for sequencing instruments.
U.S. biotech and healthcare stocks may see modest gains.
Rest‑of‑world revenue growth highlights expanding international demand for clinical consumables.
Counterpoint
If the market has already priced in the guidance lift, the stock could face a pull‑back on profit‑taking.
Key entities
- CompanyIllumina
NASDAQ‑listed genomics sequencing firm.
